An engineered T7 RNA polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis†
a
Oscar
Alvizo,
a
Scott
Baskerville,
a
Avinash
Chintala,
b
Chinping
Chng,
a
Justin
Dassie,
*a
Jonathan
Dorigatti,
a
Gjalt
Huisman,
a
Stephan
Jenne,
a
Supriya
Kadam,
a
Neil
Leatherbury,
b
Stefan
Lutz,
*a
Melissa
Mayo,
a
Arpan
Mukherjee,
b
Antoinette
Sero,
a
Stuart
Sundseth,
b
Jonathan
Penfield,
a
James
Riggins
a
and
Xiyun
Zhang
a
Abstract
Messenger RNA (mRNA) therapies have recently gained tremendous traction with the approval of mRNA vaccines for the prevention of SARS-CoV-2 infection. However, manufacturing challenges have complicated large scale mRNA production, which is necessary for the clinical viability of these therapies. Not only can the incorporation of the required 5′ 7-methylguanosine cap analog be inefficient and costly, in vitro transcription (IVT) using wild-type T7 RNA polymerase generates undesirable double-stranded RNA (dsRNA) byproducts that elicit adverse host immune responses and are difficult to remove at large scale. To overcome these challenges, we have engineered a novel RNA polymerase, T7-68, that co-transcriptionally incorporates both di- and tri-nucleotide cap analogs with high efficiency, even at reduced cap analog concentrations. We also demonstrate that IVT products generated with T7-68 have reduced dsRNA content.
- This article is part of the themed collection: Biocatalysis
Please wait while we load your content...
